Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have been given a consensus rating of “Moderate Buy” by the fourteen analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, twelve have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $137.1538.

A number of research firms have recently issued reports on ABVX. Citigroup reissued a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. Piper Sandler reaffirmed an “overweight” rating and issued a $142.00 price objective on shares of Abivax in a research note on Tuesday, December 16th. Barclays increased their target price on shares of Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Guggenheim reissued a “buy” rating and set a $175.00 target price on shares of Abivax in a research report on Thursday, December 18th. Finally, Morgan Stanley boosted their price target on shares of Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, January 9th.

Institutional Investors Weigh In On Abivax

Hedge funds and other institutional investors have recently bought and sold shares of the company. Hsbc Holdings PLC purchased a new position in Abivax during the 4th quarter worth $462,000. Bank of Hawaii grew its position in Abivax by 14.9% during the 4th quarter. Bank of Hawaii now owns 3,454 shares of the company’s stock worth $466,000 after purchasing an additional 448 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of Abivax by 9,421.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,951 shares of the company’s stock worth $668,000 after buying an additional 4,899 shares during the last quarter. Dorsey Wright & Associates acquired a new stake in shares of Abivax during the fourth quarter worth $2,241,000. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Abivax in the 4th quarter valued at $61,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Abivax Price Performance

ABVX stock opened at $102.47 on Monday. Abivax has a 12 month low of $4.77 and a 12 month high of $148.83. The firm’s 50-day moving average is $118.39 and its 200 day moving average is $111.32. The company has a market capitalization of $8.11 billion, a PE ratio of -19.08 and a beta of 1.01.

Abivax (NASDAQ:ABVX) last issued its earnings results on Monday, March 23rd. The company reported ($1.20) EPS for the quarter, topping analysts’ consensus estimates of ($2.24) by $1.04. The company had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $1.80 million. Sell-side analysts forecast that Abivax will post -2.83 EPS for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.